Selective activation of cannabinoid CB2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation

Neuroscience

Volumn 119, Issue 3, 2003, Pages 747-757

  Nackley, A G ^a   Makriyannis, A ^b   Hohmann, A G ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Allodynia; Carrageenan; Dorsal horn; Endocannabinoid; Hyperalgesia; Peripheral analgesia

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CARRAGEENAN; PROTEIN FOS; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HYPERALGESIA; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MALE; MECHANICAL STIMULATION; NERVE CELL; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN; STIMULUS RESPONSE; THERMAL STIMULATION;

EID: 0038521050     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00126-X     Document Type: Article

References (59)

1. Ahluwalia J., Urban L., Bevan S., Capogna M., Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience. 110:2002;747-753.
2. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
3. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor adenylate cyclase inhibition and G protein coupling . FEBS Lett. 375:1995;143-147.
4. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 396:2000;141-149.
5. B receptor-mediated events to inflammatory pain processing carrageenan oedema and associated spinal c-Fos expression in the rat . Neuroscience. 73:1996;487-496.
6. Buritova J., Chapman V., Honore P., Besson J.M. The contribution of peripheral bradykinin B2 receptors to carrageenan-evoked oedema and spinal c-Fos expression in rats. Eur J Pharmacol. 320:1997;73-80.
7. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
8. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 419:2001;191-198.
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53:1994;55-63.
10. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology. 41:2001;870-877.
11. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 96:2002;253-260.
12. 35S]GTP gamma S binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci. 12:2000;2079-2086.
13. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 92:1995;3376-3380.
14. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513.
15. Farquhar-Smith W.P., Jaggar S.I., Rice A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. 97:2002;11-21.
16. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-450.
17. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 232:1995;54-61.
18. Greenhouse S.W., Geisser S. On methods in the analysis of profile data. Psychometrika. 24:1959;95-112.
19. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., Fride E. HU-308 a specific agonist for CB(2), a peripheral cannabinoid receptor . Proc Natl Acad Sci USA. 96:1999;14228-14233.
20. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
21. Harris J., Liam J., Chapman D., Chapman V. Spinal anandamine inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport. 2000;2817-2819.
22. Hedo G., Laird J.M.A., Lopez-Garcia J.A. Time-course of spinal sensitization following carrageenan-induced inflammation in the young rat a comparative electrophysiological and behavioural study in vitro and in vivo . Neuroscience. 92:1998;309-318.
23. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
24. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia a double-label in situ hybridization study . Neuroscience. 90:1999;923-931.
25. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, 212-2. Life Sci. 56:1995;2111-2118.
26. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55, 212-2. Neurosci Lett. 257:1998;119-122.
27. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 81:1999;575-583.
28. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord comparison with morphine . Acta Pharmacol Sinica. 20:1999;1132-1136.
29. Honore P., Buritova J., Besson J.M. Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat. Br J Pharmacol. 118:1996;671-680.
30. Honore P., Catheline G., Le Guen S., Besson J.M. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats. Pain. 71:1997;99-108.
31. Honore P., Chapman V., Buritova J., Besson J.M. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Brain Res. 705:1995;91-96.
32. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques a comparison between ABC and unlabeled antibody (PAP) procedures . J Histochem Cytochem. 29:1981;577-580.
33. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
34. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain. 93:2001;303-315.
35. Joris J., Costello A., Dubner R., Hargreaves K.M. Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain. 43:1990;95-103.
36. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys a peripheral cannabinoid action . Psychopharmacology (Berl). 143:1999;322-326.
37. Lambert D.M., DiPaolo F.G., Sonveaux P., Kanyonyo M., Govaerts S.J., Hermans E., Bueb J., Delzenne N.M., Tschirhart E.J. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta. 1440:1999;266-274.
38. Lambert D.M., Di Marzo V. The palmitoylethanolamide and oleamide enigmas are these two fatty acid amides cannabimimetic? Curr Med Chem. 6:1999;757-773.
39. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat implications for receptor-mediated immune modulation by cannabinoids . J Pharmacol Exp Ther. 268:1994;1612-1623.
40. Malan T.P. Jr, Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB(2) cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
41. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist correlation between electrophysiological and antinociceptive effects . J Neurosci. 16:1996;6601-6611.
42. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett. 242:1998;33-36.
43. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
44. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
45. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 300:1996;227-236.
46. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
47. Nackley, AG, Suplita, RL, Hohmann, AG (2003) A peripheral cannabinoid mechanism suppresses spinal Fos protein-expression and pain behavior in a rat model of inflammation. Neuroscience 117:659-670.
48. Noguchi K., Dubner R., Ruda M.A. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience. 46:1992;561-570.
49. Noguchi K., Kowalski K., Traub R., Solodkin A., Iadarola M.J., Ruda M.A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Brain Res Mol Brain Res. 10:1991;227-233.
50. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., MacEwan D.J., Scott R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones implications for antinociception . Neuropharmacology. 40:2001;221-232.
51. Presley R.W., Menetrey D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J Neurosci. 10:1990;323-335.
52. Price T.J., Dussor G.D., Hargreaves K.M., Flores C.M. Expression and distribution of cannabinoid receptor subtypes in trigeminal ganglion colocalization with nociceptive markers . Soc Neurosci Abst. 31:2001;716.13.
53. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119.
54. Rice A.S., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain spinal and peripheral analgesia in inflammation and neuropathy . Prostaglandins Leukot Essent Fatty Acids. 66:2002;243-256.
55. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2) identification of cannabinoid receptor subtype selective ligands . J Pharmacol Exp Ther. 278:1996;989-999.
56. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
57. Tsou K., Patrick S.L., Walker J.M. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol. 280:1995;R13-15.
58. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 96:1999;5780-5785.
59. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.